Anixa Biosciences (ANIX)
Develops cancer vaccines and ovarian-cancer CAR-T therapy through institutional collaborations.
Something off on this page? Send us feedback.
Develops cancer vaccines and an ovarian-cancer CAR-T therapy, alongside limited legacy patent licensing. The development model advances licensed technologies with research institutions and subcontractors; revenue-generating operations are not anticipated for the foreseeable future.
Cancer Vaccines and CAR-T Therapies are the primary reportable businesses, with Other including limited legacy patent licensing. Cancer Vaccines covers breast- and ovarian-cancer vaccines and early discovery work for lung, colon, and prostate cancers; CAR-T Therapies centers on an ovarian-cancer program.
Development relies on licensed technology and collaboration with Moffitt, Cleveland Clinic, and subcontractors rather than a large internal organization. The breast-cancer vaccine and CAR-T therapeutic are in clinical development, while the ovarian vaccine is preclinical.
The work is concentrated in cancer immunotherapy. Commercialization depends on successful development, regulatory approvals, and the ability to work with partners.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $7 | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $13.9M · Total debt $174.0K · Total assets $15.1M · Shareholders' equity $14.5M
- Revenue
- $0
- Operating income
- −$2.7M
- Net income
- −$2.6M
No dividends on record.
| Institutions | 15.40% | 5.36M shares | |
|---|---|---|---|
| 66 holders · as of Jun 30, 2026 | |||
| Insiders | 28.39% | 9.87M shares | |
| 4 holders · as of Sep 14, 2026 | |||
| Other | 56.21% | 19.54M shares | |
| remainder | |||
34.76M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Amit Kumar1Insiderdirector, officer: Chief Executive Officer | 18.03% | 6.17M | filed Sep 14, 2026 |
Michael Catelani2Insiderofficer: President, COO, & CFO | 7.10% | 2.47M | filed Jan 6, 2026 |
Vanguard Capital Management LLCInstitution | 3.83% | 1.33M | as of Jun 30, 2026 |
Lewis H. jr TittertonInsiderdirector | 2.87% | 996,967 | filed Sep 14, 2026 |
UBS Group AGInstitution | 1.68% | 585,430 | as of Jun 30, 2026 |
- Amit Kumar's transaction reports restate only vehicles that traded; the 2025 ownership statement (6.17M) plus the 95.7K net shares acquired since is used instead.
- Michael Catelani's transaction reports restate only vehicles that traded; the 2026 ownership statement (2.47M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +8,000 | $2.76 |
| Sep 10, 2026 | Lewis H. jr Titterton | director | +10,000 | $2.73 |
| Jul 31, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +5,000 | $3.47 |
| Jul 27, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +8,188 | $3.41 |
| Jul 24, 2026 | Amit Kumar | director, officer: Chief Executive Officer | +3,000 | $3.73 |
- Greenwich LifeSciences
Phase III peptide vaccine for breast-cancer recurrence prevention
- Immatics
PRAME-directed TCR-T therapy in clinical ovarian-cancer studies
- Elicio Therapeutics
Lymph-node-targeted therapeutic cancer vaccine for KRAS tumors
- PDS Biotechnology
Phase III immunotherapy for HPV16-positive head-and-neck cancer
- Iovance Biotherapeutics
Autologous TIL cell-therapy platform for solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anixa Biosciences | $2.71 | −2.87% | $94.9M | — | — | — | — |
| Greenwich LifeSciences | $17.63 | −9.50% | $285.9M | — | — | — | — |
| Immatics | $8.65 | −2.46% | $1.19B | — | — | 25.0 | +113.0% |
| Elicio Therapeutics | $1.90 | +1.60% | $35.7M | — | — | — | — |
| PDS Biotechnology | $0.8432 | −7.34% | $50.9M | — | — | — | — |
| Iovance Biotherapeutics | $10.29 | −3.29% | $4.75B | — | — | 14.6 | +65.7% |
| Median | — | — | 19.8 | +89.3% |